{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T22:38:06Z","timestamp":1720564686588},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","medical-hypotheses.com","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medical Hypotheses"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1016\/j.mehy.2016.07.015","type":"journal-article","created":{"date-parts":[[2016,7,26]],"date-time":"2016-07-26T11:03:40Z","timestamp":1469531020000},"page":"148-150","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Changes in metabolic profile, iron and ferritin levels during the treatment of metastatic renal cancer \u2013 A new potential biomarker?"],"prefix":"10.1016","volume":"94","author":[{"given":"Marin","family":"Gol\u010di\u0107","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marija","family":"Petkovi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.mehy.2016.07.015_b0005","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/nrurol.2010.46","article-title":"Epidemiology and risk factors for kidney cancer","volume":"7","author":"Chow","year":"2010","journal-title":"Nat Rev Urol"},{"issue":"5","key":"10.1016\/j.mehy.2016.07.015_b0010","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s11864-003-0039-2","article-title":"Metastatic renal cell carcinoma","volume":"4","author":"Flanigan","year":"2003","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.mehy.2016.07.015_b0015","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1056\/NEJMc1400731","article-title":"Overall survival in renal-cell Carcinoma with pazopanib versus sunitinib","volume":"370","author":"Motzer","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.mehy.2016.07.015_b0020","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1093\/jnci\/djk008","article-title":"Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib","volume":"99","author":"Rini","year":"2007","journal-title":"J Natl Cancer Inst"},{"issue":"15","key":"10.1016\/j.mehy.2016.07.015_b0025","article-title":"Synergistic survival: a new phenomenon connected to adverse events of first-line sunitinib treatment in advanced renal cell carcinoma","volume":"S1558\u20137673","author":"Nagyiv\u00e1nyi","year":"2015","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.mehy.2016.07.015_b0030","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1161\/CIR.0b013e3182160726","article-title":"Triglycerides and cardiovascular disease: a scientific statement from the american heart association","volume":"123","author":"Miller","year":"2011","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.mehy.2016.07.015_b0035","doi-asserted-by":"crossref","first-page":"e101","DOI":"10.1016\/j.clgc.2014.08.009","article-title":"Hyperlipidemia and hypothyroidism among metastatic renal cell carcinoma patients taking sunitinib malate. Related or unrelated adverse events?","volume":"13","author":"Tassi","year":"2015","journal-title":"Clin Genitourin Cancer"},{"issue":"5","key":"10.1016\/j.mehy.2016.07.015_b0040","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s11745-010-3409-0","article-title":"The effects of ezetimibe and\/or orlistat on triglyceride-rich lipoprotein metabolism in obese hypercholesterolemic patients","volume":"45","author":"Nakou","year":"2010","journal-title":"Lipids"},{"issue":"2","key":"10.1016\/j.mehy.2016.07.015_b0045","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.cmet.2014.05.022","article-title":"Blocking lipid synthesis overcomes tumor regrowth and metastasis after antiangiogenic therapy withdrawal","volume":"20","author":"Sounni","year":"2014","journal-title":"Cell Metab"},{"issue":"7","key":"10.1016\/j.mehy.2016.07.015_b0050","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.18632\/oncotarget.1834","article-title":"Advanced gynecologic malignancies treated with a combination of the VEGF inhibitor bevacizumab and the mTOR inhibitor temsirolimus","volume":"5","author":"Piha-Paul","year":"2014","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.mehy.2016.07.015_b0055","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s13539-013-0113-y","article-title":"A pilot study of temsirolimus and body composition","volume":"4","author":"Veasey-Rodrigues","year":"2013","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"10","key":"10.1016\/j.mehy.2016.07.015_b0060","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1634\/theoncologist.2008-0120","article-title":"Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies","volume":"13","author":"Hutson","year":"2008","journal-title":"Oncologist"},{"issue":"18","key":"10.1016\/j.mehy.2016.07.015_b0065","doi-asserted-by":"crossref","first-page":"15499","DOI":"10.1074\/jbc.M200427200","article-title":"Platelet-derived growth factor (PDGF)-induced tyrosine phosphorylation of the low density lipoprotein receptor \u2013 related protein (LRP). Evidence for integrated co-receptor function between LRP and the PDGF","volume":"277","author":"Loukinova","year":"2002","journal-title":"J Biol Chem"},{"issue":"6","key":"10.1016\/j.mehy.2016.07.015_b0070","doi-asserted-by":"crossref","first-page":"E615","DOI":"10.1152\/ajpendo.00035.2011","article-title":"Sunitinib induces apoptosis in pheochromocytoma tumor cells by inhibiting VEGFR2\/Akt\/mTOR\/S6K1 pathways through modulation of Bcl-2 and BAD","volume":"302","author":"Saito","year":"2012","journal-title":"Am J Physiol Endocrinol Metab."},{"issue":"4","key":"10.1016\/j.mehy.2016.07.015_b0075","first-page":"1951","article-title":"Targeting mTOR and AREG with everolimus, sunitinib and sorafenib in HPV-positive and negative SCC","volume":"35","author":"Aderhold","year":"2015","journal-title":"Anticancer Res"},{"issue":"2","key":"10.1016\/j.mehy.2016.07.015_b0080","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.cell.2012.03.017","article-title":"MTOR signaling in growth control and disease","volume":"149","author":"Laplante","year":"2012","journal-title":"Cell"},{"issue":"12","key":"10.1016\/j.mehy.2016.07.015_b0085","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1016\/j.leukres.2015.09.016","article-title":"Metformin synergistically sensitizes FLT3-ITD-positive acute myeloid leukemia to sorafenib by promoting mTOR-mediated apoptosis and autophagy","volume":"39","author":"Wang","year":"2015","journal-title":"Leuk Res"},{"issue":"5","key":"10.1016\/j.mehy.2016.07.015_b0090","first-page":"645","article-title":"mTOR Regulates Cellular Iron Homeostasis through Tristetraprolin","volume":"16","author":"Bayeva","year":"2012"},{"key":"10.1016\/j.mehy.2016.07.015_b0095","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1158\/0008-5472.CAN-10-3614","article-title":"Ironing out cancer","volume":"71","author":"Torti","year":"2011","journal-title":"Cancer Res"}],"container-title":["Medical Hypotheses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987716303942?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987716303942?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,10]],"date-time":"2018-09-10T07:51:22Z","timestamp":1536565882000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0306987716303942"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":19,"alternative-id":["S0306987716303942"],"URL":"https:\/\/doi.org\/10.1016\/j.mehy.2016.07.015","relation":{},"ISSN":["0306-9877"],"issn-type":[{"value":"0306-9877","type":"print"}],"subject":[],"published":{"date-parts":[[2016,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Changes in metabolic profile, iron and ferritin levels during the treatment of metastatic renal cancer \u2013 A new potential biomarker?","name":"articletitle","label":"Article Title"},{"value":"Medical Hypotheses","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mehy.2016.07.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}